Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Crohn's disease: research progress in decoding pathogenic multi-network and precision management of artificial intelligence radiomics

Zhang W., Xie H., Ying S., Zeng X., Liao X., Hu S.

Narrative Review on Autoimmune Research, published in Front Immunol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Immunol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41909686
PMCID
PMC13018164
DOI
10.3389/fimmu.2026.1774889

Abstract (original English)

Crohn's disease (CD) is a chronic, relapsing inflammatory bowel disease characterized by transmural inflammation. Its clinical presentation and disease course are highly heterogeneous across individuals, and the global disease burden continues to rise. Although biomarkers such as fecal calprotectin and anti-Saccharomyces cerevisiae antibodies (ASCA), together with computed tomography enterography (CTE)/magnetic resonance enterography (MRE) and endoscopy, play central roles in diagnosis and longitudinal monitoring, important unmet needs remain. In particular, current approaches show limited reproducibility and insufficient phenotypic granularity for stratifying transmural inflammation, mesenteric involvement, and fibrostenotic disease, as well as for predicting therapeutic response and surgical risk. In this review, we adopt a multi-network pathogenic framework-encompassing genetic susceptibility, barrier dysfunction, microbial dysbiosis, immune-driven inflammation, fibrotic remodeling, and mesenteric inflammation with adipose remodeling-to delineate how these interconnected processes shape intestinal and mesenteric imaging phenotypes. We then focus on AI-enabled radiomics in CTE/MRE, summarizing key workflows for phenotype quantification, feature extraction, and model development, and highlighting its potential as an imaging biomarker across major clinical applications, includi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansCrohn DiseaseMagnetic Resonance ImagingArtificial IntelligenceBiomarkersPrecision MedicineRadiomics

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research